Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Melanoma × Sodium Chloride × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Carcinoma, Non-Small-Cell Lung 5 Neoplasms 3 Glioblastoma 3 Colorectal Neoplasms 3 Skin Neoplasms 2 Ovarian Neoplasms 2 Myelodysplastic Syndromes 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Hot Flashes 2 Vulvodynia 1 Thromboembolism 1 Recurrence 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Postoperative Hemorrhage 1 Pleural Effusion, Malignant 1 Platinum Resistant Ovarian Cancer 1 Parathyroid Neoplasms 1 Pancreatic Neoplasms 1 Pain, Postoperative 1 Neutropenia 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Myasthenia Gravis 1 Multiple Myeloma 1 Multiple Endocrine Neoplasia Type 1 1 Melanoma 1

Interventions

Ipilimumab 79 pembrolizumab 71 Nivolumab 68 aldesleukin 46 Cyclophosphamide 44 Interleukin-2 33 fludarabine phosphate 30 Vemurafenib 29 Dacarbazine 28 trametinib 25 fludarabine 25 dabrafenib 25 Temozolomide 21 Bevacizumab 15 Radiosurgery 14 binimetinib 12 Paclitaxel 12 Introns 12 Interferon alpha-2 12 Carboplatin 11 CTLA-4 Antigen 11 peginterferon alfa-2b 9 montanide ISA 51 9 encorafenib 9 cobimetinib 9 Radiotherapy 9 talimogene laherparepvec 8 atezolizumab 8 Sorafenib 8 spartalizumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03233828 2024-07-24

IL-2

Nova Scotia Health Authority

Phase 3 Terminated

1 enrolled 3 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡